---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-036109"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T04:45:22.666928+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oramed invests $36.9M in Alpha Tau, acquires 14.1M shares at $2.612/share

## Summary
- Oramed subsidiary purchased ~14.1M shares of Alpha Tau (NASDAQ: DRTS) for $36.9M ($2.612/share) via registered direct offering.
- Oramed gets right to nominate two directors to Alpha Tau board; board size capped at 8 without Oramed's consent.
- Concurrent 3-year IR/PR services agreement; Oramed receives $3M fee plus warrants to buy ~3.24M shares at $3.474-$3.90.
- Partnership aims to support Alpha Tau's alpha-radiation cancer therapy Alpha DaRT, including US trials and manufacturing scale-up.
- Oramed CEO Nadav Kidron cites alignment in transforming therapeutic delivery; governance role allows strategic influence.

## SEC filing metadata
- accession: 0001213900-25-036109
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390025036109/0001213900-25-036109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390025036109/ea0239800-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-036109
- JSON: https://secwatch.observer/filing/0001213900-25-036109.json
- Plain text: https://secwatch.observer/filing/0001213900-25-036109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.